A class of tricyclic compounds blocking malaria parasite oocyst development and transmission

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 425-435

  Eastman, Richard T ^a   Pattaradilokrat, Sittiporn ^a,b   Raj, Dipak K ^a,d   Dixit, Saurabh ^a   Deng, Bingbing ^a   Miura, Kazutoyo ^a   Yuan, Jing ^a   Tanaka, Takeshi Q ^a   Johnson, Ronald L ^c,e   Jiang, Hongying ^a   Huang, Ruili ^c   Williamson, Kim C ^a   Lambert, Lynn E ^a   Long, Carole ^a   Austin, Christopher P ^c   Wu, Yimin ^a   Su, Xin Zhuan ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTIMALARIAL AGENT; CHLORPROMAZINE; CYPROHEPTADINE; DOXIPIN; IMIPRAMINE; KETOTIFEN; MLS 000556883 02; MLS 000556884 02; MLS 000708402 02; PIZOTIFEN; PRIMAQUINE; PROTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMALARIAL ACTIVITY; ARTICLE; ASEXUAL SPORE; CONTROLLED STUDY; DRUG STRUCTURE; GAMETOCYTE; MALARIA; METABOLISM; MOSQUITO; MOUSE; NONHUMAN; OOCYST; PARASITE TRANSMISSION; PLASMODIUM; PLASMODIUM CYNOMOLGI; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; RHESUS MONKEY;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTIMALARIALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; DRUG REPOSITIONING; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KETOTIFEN; MACACA MULATTA; MALARIA; MALARIA, FALCIPARUM; MICE; OOCYSTS; PLASMODIUM CYNOMOLGI; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PROTOZOAN PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 84872040862     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00920-12     Document Type: Article

References (68)

1. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, Duffy PE. 2008. Malaria: progress, perils, and prospects for eradication. J. Clin. Invest. 118:1266-1276.
2. WHO. 2010. World malaria report. WHO, Geneva, Switzerland. http://www.who.int/malaria/world-malaria-report-2010/en/index.html.
3. White NJ. 2008. Qinghaosu (artemisinin): the price of success. Science 320:330-334.
4. Kilama W, Ntoumi F. 2009. Malaria: a research agenda for the eradication era. Lancet 374:1480-1482.
5. White NJ. 2008. The role of anti-malarial drugs in eliminating malaria. Malar. J. 7(Suppl. 1):S8.
6. Shekalaghe SA, Drakeley C, van den Bosch S, Ter Braak R, van den Bijllaardt W, Mwanziva C, Semvua S, Masokoto A, Mosha F, Teelen K, Hermsen R, Okell L, Gosling R, Sauerwein R, Bousema T. 2011. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malar. J. 10:247.
7. Song J, Socheat D, Tan B, Dara P, Deng C, Sokunthea S, Seila S, Ou F, Jian H, Li G. 2010. Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar. J. 9:57.
8. Baird JK, Surjadjaja C. 2011. Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol. 27:11-16.
9. Cohen RJ, Sachs JR, Wicker DJ, Conrad ME. 1968. Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N. Engl. J. Med. 279:1127-1131.
10. Wells TN, Burrows JN, Baird JK. 2010. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 26:145-151.
11. Olliaro P, Wells TN. 2009. The global portfolio of new antimalarial medicines under development. Clin. Pharmacol. Ther. 85:584-595.
12. Adjalley SH, Johnston GL, Li T, Eastman RT, Ekland EH, Eappen AG, Richman A, Sim BK, Lee MC, Hoffman SL, Fidock DA. 2011. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc. Natl. Acad. Sci. U. S. A. 108:E1214-E1223.
13. Buchholz K, Burke TA, Williamson KC, Wiegand RC, Wirth DF, Marti M. 2011. A high-throughput screen targeting malaria transmission stages opens new avenues for drug development. J. Infect. Dis. 203:1445-1453.
14. Tanaka TQ, Williamson KC. 2011. A malaria gametocytocidal assay using oxidoreduction indicator, alamarBlue. Mol. Biochem. Parasitol. 177:160-163.
15. Dean M, Annilo T. 2005. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Hum. Genet. 6:123-142.
16. Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ, Cowman AF. 1990. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 345:255-258.
17. Hayton K, Su X-Z. 2004. Genetic and biochemical aspects of drug resistance in malaria parasites. Curr. Drug Targets Infect. Disord. 4:1-10.
18. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. 2000. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403:906-909.
19. Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ. 2009. Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nat. Chem. Biol. 5:765-771.
20. Rosenberg E, Litus I, Schwarzfuchs N, Sinay R, Schlesinger P, Golenser J, Baumeister S, Lingelbach K, Pollack Y. 2006. pfmdr2 confers heavy metal resistance to Plasmodium falciparum. J. Biol. Chem. 281:27039-27045.
21. Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T, Subramanian G, Aravind L, Cooper RA, Wootton JC, Xiong M, Su X-Z. 2003. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol. Microbiol. 49:977-989.
22. Raj DK, Mu J, Jiang H, Kabat J, Singh S, Sullivan M, Fay MP, McCutchan TF, Su X-Z. 2009. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J. Biol. Chem. 284:7687-7696.
23. Martin RE, Henry RI, Abbey JL, Clements JD, Kirk K. 2005. The 'permeome' of the malaria parasite: an overview of the membrane transport proteins of Plasmodium falciparum. Genome Biol. 6:R26. doi:10.1186/gb-2005-6-3-r26.
24. Doyle LA, Ross DD. 2003. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358.
25. Krishnamurthy P, Schuetz JD. 2006. Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol. 46:381-410.
26. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, Nguyen DT, Austin CP. 2011. The NCGC Pharmaceutical Collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med. 3:80ps16. doi:10.1126/scitranslmed.3001862.
27. Le Roch KG, Zhou Y, Blair PL, Grainger M, Moch JK, Haynes JD, De La Vega P, Holder AA, Batalov S, Carucci DJ, Winzeler EA. 2003. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 301:1503-1508.
28. Young JA, Fivelman QL, Blair PL, de la Vega P, Le Roch KG, Zhou Y, Carucci DJ, Baker DA, Winzeler EA. 2005. The Plasmodium falciparum sexual development transcriptome: a microarray analysis using ontology-based pattern identification. Mol. Biochem. Parasitol. 143:67-79.
29. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
30. Furuya T, Mu J, Hayton K, Liu A, Duan J, Nkrumah L, Joy DA, Fidock DA, Fujioka H, Vaidya AB, Wellems TE, Su X-Z. 2005. Disruption of a Plasmodium falciparum gene linked to male sexual development causes early arrest in gametocytogenesis. Proc. Natl. Acad. Sci. U. S. A. 102:16813-16818.
31. Duraisingh MT, Triglia T, Cowman AF. 2002. Negative selection of Plasmodium falciparum reveals targeted gene deletion by double crossover recombination. Int. J. Parasitol. 32:81-89.
32. Eastman RT, Dharia NV, Winzeler EA, Fidock DA. 2011. Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob. Agents Chemother. 55:3908-3916.
33. Wu Y, Sifri CD, Lei HH, Su XZ, Wellems TE. 1995. Transfection of Plasmodium falciparum within human red blood cells. Proc. Natl. Acad. Sci. U. S. A. 92:973-977.
34. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 48:1803-1806.
35. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, Zheng W, Austin CP. 2006. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. U. S. A. 103:11473-11478.
36. Yuan J, Cheng KC, Johnson RL, Huang R, Pattaradilokrat S, Liu A, Guha R, Fidock DA, Inglese J, Wellems TE, Austin CP, Su XZ. 2011. Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science 333:724-729.
37. Slater JW, Zechnich AD, Haxby DG. 1999. Second-generation antihistamines: a comparative review. Drugs 57:31-47.
38. Grant SM, Goa KL, Fitton A, Sorkin EM. 1990. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 40:412-448.
39. Gupta S, Popli A, Bathurst E, Hennig L, Droney T, Keller P. 1998. Efficacy of cyproheptadine for nightmares associated with post-traumatic stress disorder. Compr. Psychiatry 39:160-164.
40. Milner E, Sousa J, Pybus B, Auschwitz J, Caridha D, Gardner S, Grauer K, Harris E, Hickman M, Kozar MP, Lee P, Leed S, Li Q, Melendez V, Moon J, Ngundam F, O'Neil M, Parriott S, Potter B, Sciotti R, Tangteung A, Dow GS. 5 February 2012. Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy. Eur. J. Drug Metab. Pharmacokinet. [Epub ahead of print.] doi:10/1007/s13318-0080-2.
41. Grahnen A, Lonnebo A, Beck O, Eckernas SA, Dahlstrom B, Lindstrom B. 1992. Pharmacokinetics of ketotifen after oral administration to healthy male subjects. Biopharm. Drug Dispos. 13:255-262.
42. Basco LK, Ringwald P, Le Bras J. 1991. Chloroquine-potentiating action of antihistaminics in Plasmodium falciparum in vitro. Ann. Trop. Med. Parasitol. 85:223-228.
43. Bitonti AJ, McCann PP. 1989. Desipramine and cyproheptadine for reversal of chloroquine resistance in Plasmodium falciparum. Lancet ii:1282-1283.
44. Henry M, Alibert S, Baragatti M, Mosnier J, Baret E, Amalvict R, Legrand E, Fusai T, Barbe J, Rogier C, Pages JM, Pradines B. 2008. Dihydroethanoanthracene derivatives reverse in vitro quinoline resistance in Plasmodium falciparum malaria. Med. Chem. 4:426-437.
45. Kyle DE, Milhous WK, Rossan RN. 1993. Reversal of Plasmodium falciparum resistance to chloroquine in Panamanian Aotus monkeys. Am. J. Trop. Med. Hyg. 48:126-133.
46. Peters W, Ekong R, Robinson BL, Warhurst DC, Pan XQ. 1989. Antihistaminic drugs that reverse chloroquine resistance in Plasmodium falciparum. Lancet ii:334-335.
47. Quan H, Tang LH. 2008. In vitro potentiation of chloroquine activity in Plasmodium falciparum by ketotifen and cyproheptadine. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 26:338-342. (In Chinese.)
48. Singh N, Puri SK. 2000. Interaction between chloroquine and diverse pharmacological agents in chloroquine resistant Plasmodium yoelii nigeriensis. Acta Trop. 77:185-193.
49. Sowunmi A. 2003. A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. Ann. Trop. Med. Parasitol. 97:103-117.
50. Sowunmi A, Fateye BA. 2003. Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs. Trop. Med. Int. Health 8:783-792.
51. Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, Deen J, Pinder M, Doherty T, Sutherland C, Walraven G, Milligan P. 2001. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J. Infect. Dis. 183:1254-1259.
52. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D. 2012. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 9:e1001169. doi:10.1371/journal.pmed.1001169.
53. Dembele L, Gego A, Zeeman AM, Franetich JF, Silvie O, Rametti A, Le Grand R, Dereuddre-Bosquet N, Sauerwein R, van Gemert GJ, Vaillant JC, Thomas AW, Snounou G, Kocken CH, Mazier D. 2011. Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS One 6:e18162. doi:10.1371/journal. pone.0018162.
54. Dean M. 2005. The genetics of ATP-binding cassette transporters. Methods Enzymol. 400:409-429.
55. Sarkadi B, Homolya L, Szakacs G, Varadi A. 2006. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev. 86:1179-1236.
56. Sidhu AB, Valderramos SG, Fidock DA. 2005. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol. Microbiol. 57:913-926.
57. Sidhu AB, Verdier-Pinard D, Fidock DA. 2002. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298:210-213.
58. Wu Y, Wellems TE. 1996. Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Proc. Natl. Acad. Sci. U. S. A. 93:1130-1134.
59. Zhang Y, Berger SA. 2003. Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo. Cancer Chemother. Pharmacol. 51:407-414.
60. Brenner C. 2004. Chemical genomics in yeast. Genome Biol. 5:240. doi:10.1186/gb-2004-5-9-240.
61. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM. 2004. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6:129-137.
62. Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ, Jr. 2006. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat. Chem. Biol. 2:415-416.
63. Gamo FJ, Sanz LM, Vidal J, DE Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR, Peishoff CE, Cardon LR, Garcia-Bustos JF. 2010. Thousands of chemical starting points for antimalarial lead identification. Nature 465:305-310.
64. Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, Smithson DC, Connelly M, Clark J, Zhu F, Jimenez-Diaz MB, Martinez MS, Wilson EB, Tripathi AK, Gut J, Sharlow ER, Bathurst I, El Mazouni F, Fowble JW, Forquer I, McGinley PL, Castro S, Angulo-Barturen I, Ferrer S, Rosenthal PJ, Derisi JL, Sullivan DJ, Lazo JS, Roos DS, Riscoe MK, Phillips MA, Rathod PK, Van Voorhis WC, Avery VM, Guy RK. 2010. Chemical genetics of Plasmodium falciparum. Nature 465:311-315.
65. Kato N, Sakata T, Breton G, Le Roch KG, Nagle A, Andersen C, Bursulaya B, Henson K, Johnson J, Kumar KA, Marr F, Mason D, McNamara C, Plouffe D, Ramachandran V, Spooner M, Tuntland T, Zhou Y, Peters EC, Chatterjee A, Schultz PG, Ward GE, Gray N, Harper J, Winzeler EA. 2008. Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. Nat. Chem. Biol. 4:347-356.
66. Weisman JL, Liou AP, Shelat AA, Cohen FE, Guy RK, DeRisi JL. 2006. Searching for new antimalarial therapeutics amongst known drugs. Chem. Biol. Drug Des. 67:409-416.
67. Chattopadhyay R, Velmurugan S, Chakiath C, Andrews Donkor L, Milhous W, Barnwell JW, Collins WE, Hoffman SL. 2010. Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria. PLoS One 5:e14275. doi:10.1371/journal.pone.0014275.
68. Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA. 2011. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334:1372-1377.